Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient

International Journal of STD and AIDS

Volumn 19, Issue 3, 2008, Pages 208-210

  Coriat, Romain ^a   Podevin, Philippe ^b  

^a Hôpital Cochin ^*  (France)

^b UniversitéRenéDescartes   (France)

Author keywords

Hepatitis C; Human immunodeficiency virus; Viral disease

Indexed keywords

ATAZANAVIR; AZITHROMYCIN; EFAVIRENZ; INTERFERON; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; RITONAVIR; STEROID;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; DEATH; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; PRIORITY JOURNAL; SCORING SYSTEM; STEROID THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 44349103597     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2007.007185     Document Type: Article

References (17)

1. Salmon-Céron DCL, Lewden C, Morlat P, et al. The Mortality 2000 Study Group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42:799-805
2. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006;42:673-6
3. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12
4. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9
6. Torriani FJ, Rodriguez-Torres M, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
7. Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 2003;36:519-23
8. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38
9. French M, Price P, Stone S. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27
10. Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 2005;51:55-61
11. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-44
12. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7
13. Biron C. Interferons a and b as immune regulators-A new look. Immunity 2001;14:661-4
14. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83
15. Harada K, Van de Water J, Leung PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997;25:791-6
16. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplant patients treated with peg-Interferon alfa-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56:237-42
17. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95